Objective
To assess whether preventive percutaneous coronary intervention (PCI) of non-flow limiting vulnerable plaques improves clinical outcomes compared with optimal medical therapy alone
Study
Investigator initiated, open-label, randomised controlled trial
Population
Patients with coronary artery disease with intermediate, non-flow limiting, vulnerable plaque
Endpoints
The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischaemia-driven target-vessel revascularisation, or hospitalisation for unstable or progressive angina, all at 2 years after randomisation
Conclusion
Preventive PCI plus optimal medical therapy resulted in a lower incidence of major adverse cardiac events during long-term follow-up, compared with optimal medical therapy alone.
Park et al. Lancet 2024
